Should we still use azithromycin for gonorrhoea treatment?

This review presents the evidence for azithromycin in the treatment of gonorrhoea, both as monotherapy and as a component of dual therapy. Uncertainties are explored regarding the efficacy of a dual treatment strategy, combining ceftriaxone and azithromycin, in the context of resistance trends and e...

Full description

Saved in:
Bibliographic Details
Published inSexual health Vol. 16; no. 5; pp. 442 - 448
Main Authors Mensforth, Sarah, Ross, Jonathan D C
Format Journal Article
LanguageEnglish
Published Australia CSIRO 01.01.2019
Subjects
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antimicrobial agents
Azithromycin
Azithromycin - administration & dosage
Azithromycin - therapeutic use
Ceftriaxone
Chlamydia
Diarrhea
Drug dosages
Drug Resistance, Bacterial
Drug Therapy, Combination
Epidemiology
Gonorrhea
Gonorrhea - drug therapy
Humans
Infections
Laboratories
Mutation
Neisseria gonorrhoeae - drug effects
Surveillance
Syphilis
Systematic review
Treatment Outcome
Vagina
United States > US
Greenland
United Kingdom > UK
Online AccessGet full text

Cover

More Information
Summary:This review presents the evidence for azithromycin in the treatment of gonorrhoea, both as monotherapy and as a component of dual therapy. Uncertainties are explored regarding the efficacy of a dual treatment strategy, combining ceftriaxone and azithromycin, in the context of resistance trends and extra-genital infections. The association between microbiological testing and clinical outcome for the individual patient, and the effect of azithromycin use on other sexually transmissible infections, are considered. Finally, in the absence of imminent new antimicrobials, optimising the dose of azithromycin while maintaining tolerability is discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1448-5028
1449-8987
DOI:10.1071/SH19016